Moore, Lauren M.
Wilkinson, Rachel
Altan, Mehmet
Toki, Maria
Carvajal-Hausdorf, Daniel E.
McGuire, John
Ehrlich, Barbara E.
Rimm, David L.
Article History
Received: 16 February 2017
Revised: 28 January 2018
Accepted: 8 February 2018
First Online: 12 March 2018
Competing interests
: In the last 24 months D.L.R. has been a consultant to Astra Zeneca, Agendia, Bethyl Labs, Biocept, BMS, Cell Signaling Technology, Cepheid, ClearSight, Genoptix/Novartis, Merck, OptraScan, Perkin Elmer, and Ultivue. D.L.R. has received grant funding from Cepheid, Genoptix, Gilead Sciences, Pierre Fabre, Perkin Elmer and Nantomics. None of these interactions are related to this work. The remaining authors declare no competing interests.